Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor.

López-Soto A, Huergo-Zapico L, Galván JA, Rodrigo L, de Herreros AG, Astudillo A, Gonzalez S.

J Immunol. 2013 Apr 15;190(8):4408-19. doi: 10.4049/jimmunol.1202950. Epub 2013 Mar 18.

2.

Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.

Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X, Ferrand C, Tiberghien P, Borg C.

Cancer Res. 2011 Mar 1;71(5):1615-26. doi: 10.1158/0008-5472.CAN-09-4540. Epub 2011 Jan 21.

3.

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

Maccalli C, Scaramuzza S, Parmiani G.

Cancer Immunol Immunother. 2009 May;58(5):801-8. doi: 10.1007/s00262-008-0635-x. Epub 2008 Dec 17. Review.

PMID:
19089424
4.

NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.

Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G.

Eur J Immunol. 2003 Jul;33(7):2033-43.

5.

TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.

Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA.

Brain. 2006 Sep;129(Pt 9):2416-25. Epub 2006 Aug 3.

PMID:
16891318
6.

Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.

Zhang C, Wang Y, Zhou Z, Zhang J, Tian Z.

Cancer Immunol Immunother. 2009 Aug;58(8):1275-85. doi: 10.1007/s00262-008-0645-8. Epub 2009 Jan 13.

PMID:
19139882
7.

Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.

Bagnato A, Rosanò L.

Cells Tissues Organs. 2007;185(1-3):85-94. Review.

PMID:
17587812
8.

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A.

Cancer Res. 2002 Nov 1;62(21):6178-86.

9.

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.

Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A.

Blood. 2003 Aug 15;102(4):1389-96. Epub 2003 Apr 24.

10.

2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation.

Andresen L, Skovbakke SL, Persson G, Hagemann-Jensen M, Hansen KA, Jensen H, Skov S.

J Immunol. 2012 Feb 15;188(4):1847-55. doi: 10.4049/jimmunol.1004085. Epub 2012 Jan 6.

11.

Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.

Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W.

Med Oncol. 2011 Jun;28(2):466-74. doi: 10.1007/s12032-010-9480-9. Epub 2010 Mar 31.

PMID:
20354827
12.

Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53.

13.

Potential role of NKG2D/MHC class I-related chain A interaction in intrathymic maturation of single-positive CD8 T cells.

Hüe S, Monteiro RC, Berrih-Aknin S, Caillat-Zucman S.

J Immunol. 2003 Aug 15;171(4):1909-17.

14.

Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin.

Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L.

Eur J Immunol. 2001 Apr;31(4):1076-86.

15.

Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.

Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR.

J Immunol. 2008 Nov 15;181(10):6711-9.

16.

Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.

Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ Jr.

Hum Gene Ther. 2013 Mar;24(3):295-305. doi: 10.1089/hum.2012.143. Epub 2013 Mar 1.

17.

Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer.

Shen Y, Lu C, Tian W, Wang L, Cui B, Jiao Y, Ma C, Ju Y, Zhu L, Shao C, Liu X, Wang J, Zhang B, Lu Z.

Int J Oncol. 2012 Apr;40(4):1285-90. doi: 10.3892/ijo.2011.1315. Epub 2011 Dec 22.

18.

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R.

J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.

19.

MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M.

Cancer Res. 2003 Dec 15;63(24):8996-9006.

20.

Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients.

Peraldi MN, Berrou J, Dulphy N, Seidowsky A, Haas P, Boissel N, Metivier F, Randoux C, Kossari N, Guérin A, Geffroy S, Delavaud G, Marin-Esteban V, Glotz D, Charron D, Toubert A.

J Immunol. 2009 Feb 1;182(3):1696-705.

Supplemental Content

Support Center